Q1 EPS Estimates for Keros Therapeutics Lifted by Wedbush

Keros Therapeutics, Inc. (NASDAQ:KROS) – Investment analysts at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for Keros Therapeutics in a report released on Tuesday, December 3rd. Wedbush analyst Y. Zhong now anticipates that the company will post earnings per share of ($1.40) for the quarter, up from their prior forecast of ($1.44). Wedbush currently has a “Outperform” rating and a $84.00 target price on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($5.28) per share. Wedbush also issued estimates for Keros Therapeutics’ Q2 2025 earnings at ($1.39) EPS, Q3 2025 earnings at ($1.37) EPS, Q4 2025 earnings at ($1.35) EPS, FY2025 earnings at ($5.51) EPS, FY2026 earnings at ($5.02) EPS, FY2027 earnings at ($4.73) EPS and FY2028 earnings at ($3.87) EPS.

Other research analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Guggenheim reissued a “buy” rating and set a $102.00 price objective (up previously from $96.00) on shares of Keros Therapeutics in a research note on Wednesday. Scotiabank initiated coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 target price for the company. Jefferies Financial Group began coverage on Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $89.56.

Keros Therapeutics Trading Up 8.3 %

KROS stock opened at $70.00 on Friday. The firm has a 50 day moving average of $60.05 and a 200-day moving average of $52.56. The firm has a market capitalization of $2.84 billion, a P/E ratio of -13.44 and a beta of 1.20. Keros Therapeutics has a 12 month low of $27.31 and a 12 month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million for the quarter. During the same period in the previous year, the firm earned ($1.33) earnings per share. The firm’s quarterly revenue was up 4750.0% on a year-over-year basis.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC lifted its stake in Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after purchasing an additional 179,374 shares during the last quarter. Alkeon Capital Management LLC lifted its stake in shares of Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after acquiring an additional 298,694 shares during the last quarter. Darwin Global Management Ltd. boosted its holdings in Keros Therapeutics by 6.3% during the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock valued at $68,772,000 after acquiring an additional 89,952 shares during the period. Point72 Asset Management L.P. grew its position in Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after acquiring an additional 577,220 shares during the last quarter. Finally, Holocene Advisors LP increased its stake in Keros Therapeutics by 22.5% in the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock worth $48,959,000 after purchasing an additional 154,784 shares during the period. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.